Filtered By:
Drug: Docetaxel
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 2210 results found since Jan 2013.
Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions
ConclusionRapid desensitisation to various chemotherapeutic agents and monoclonal antibodies with standardised protocols used across CRCS is safe and effective; it provides a feasible treatment option enabling continuation of effective regimens in the setting of HSR.
Source: Internal Medicine Journal - November 7, 2013 Category: Internal Medicine Authors: James C Kuo, Carolyn Hawkins, Desmond Yip Tags: Original Article Source Type: research
Enzalutamide (Xtandi) for Patients With Metastatic, Resistant Prostate Cancer.
CONCLUSIONS: Enzalutamide is effective to slow progression of metastatic CRPC, to reduce prostate-specific antigen (PSA) levels, to decrease time to progression of PSA, to increase time to first skeletal-related events, and to increase quality of response rate. Enzalutamide was given at 160 mg/d for a median of 8 cycles of administration. Clinical trials are currently being conducted to observe if enzalutamide will be useful for treatment of other cancers and for early administration in prostate cancer.
PMID: 24458946 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 23, 2014 Category: Drugs & Pharmacology Authors: Bennett LL, Ingason A Tags: Ann Pharmacother Source Type: research
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison.
CONCLUSION: While there was no statistically significant difference in OS, enzalutamide may be advantageous for secondary endpoints. Findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials.
PMID: 24678245 [PubMed]
Source: Clinical Prostate Cancer - April 1, 2014 Category: Cancer & Oncology Authors: Tan PS, Haaland B, Montero AJ, Kyriakopoulos CE, Lopes G Tags: Clin Med Insights Oncol Source Type: research
Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis.
The objectives of the study were to assess the efficacy and safety of post-docetaxel enzalutamide treatment and to compare it with abiraterone and with cabazitaxel, using Medline-based systematic literature search, and meta-analysis of randomised controlled trials (RCT). Overall 3 RCTs were included, one for each substance. Compared to placebo, enzalutamide proved significant efficacy in each primary and secondary endpoint. Enzalutamide extended median overall survival by 4.8 months. Due to lack of a common comparator in the cabazitaxel trial, only enzalutamide and abiraterone were involved in an indirect comparison. No si...
Source: Magyar Onkologia - September 26, 2014 Category: Cancer & Oncology Authors: Brodszky V, Péntek M, Baji P, Rencz F, Géczi L, Szûcs M, Berczi C, Gulácsi L Tags: Magy Onkol Source Type: research
Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials.
In conclusion, our findings indicated that docetaxel combined with antiangiogenic agents did not increase the OS or the PFS of the patients with castration-resistant prostate cancer, whereas it may increase the risk of treatment-related mortality. However, further RCTs with larger, high-quality patient samples are required to verify these findings.
PMID: 25279220 [PubMed - as supplied by publisher]
Source: Clinical Prostate Cancer - October 10, 2014 Category: Cancer & Oncology Authors: Lei N, Song Z, Lu B, Tan Z, Pei J, Liu W, Xu K Tags: Mol Clin Oncol Source Type: research
Hyperglycemic-inducing neoadjuvant agents used in treatment of solid tumors: a review of the literature.
CONCLUSIONS: Findings suggest patients are at risk for the development of hyperglycemia from certain chemotherapeutic agents. Docetaxel, everolimus, and temsirolimus alone or in combination with other agents can promote hyperglycemia. Androgen-deprivation therapy commonly used in prostate cancer, increases the risk for the development of hyperglycemia and diabetes.
IMPLICATIONS FOR NURSING: Oncology nurses play an important role in the identification and treatment of hyperglycemia in patients receiving chemotherapy. Future research is needed that focuses on the association between glycemic control and adverse outcomes...
Source: Oncology Nursing Forum - November 1, 2014 Category: Nursing Authors: Hershey DS, Bryant AL, Olausson J, Davis ED, Brady VJ, Hammer M Tags: Oncol Nurs Forum Source Type: research
The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma
Conclusion
A chemotherapy regimen comprising both a cell cycle-specific drug and a cell cycle-nonspecific drug could increase response rates. The combination of ifosfamide and etoposide therapy is our first choice in two-drug regimens. Regarding three-drug regimens, adding a cell cycle-specific drug to ifosfamide–etoposide therapy may result in a better response rate than adding a cell cycle-nonspecific drug, or any other two-drug regimens in current studies. Hence, we recommend the use of second-line chemotherapy based on the combination ifosfamide–etoposide regimen in patients with metastatic, relapsed and ...
Source: Pediatric Drugs - November 12, 2014 Category: Pediatrics Source Type: research
The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma.
CONCLUSION: A chemotherapy regimen comprising both a cell cycle-specific drug and a cell cycle-nonspecific drug could increase response rates. The combination of ifosfamide and etoposide therapy is our first choice in two-drug regimens. Regarding three-drug regimens, adding a cell cycle-specific drug to ifosfamide-etoposide therapy may result in a better response rate than adding a cell cycle-nonspecific drug, or any other two-drug regimens in current studies. Hence, we recommend the use of second-line chemotherapy based on the combination ifosfamide-etoposide regimen in patients with metastatic, relapsed and refractory os...
Source: Paediatric Drugs - November 13, 2014 Category: Pediatrics Authors: Xiao X, Wang W, Wang Z Tags: Paediatr Drugs Source Type: research
How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
CONCLUSIONS: A number of phase III trials have been published that describe agents which are beneficial in treating mCRPC. Future research will focus on sequencing these agents in a clinically rational and economically viable manner.
PMID: 24775730 [PubMed - in process]
Source: Canadian Journal of Urology - December 1, 2014 Category: Urology & Nephrology Tags: Can J Urol Source Type: research
Practical guide to the use of enzalutamide.
CONCLUSION: Enzalutamide is an effective oral therapy for mCRPC, with an overall survival benefit before and following chemotherapy. Toxicity is mild, and seizure risk can be mitigated by careful patient selection. Ongoing studies will help determine the best sequence of novel agents for prostate cancer, along with safe and effective combinations of therapies. Better understanding of tumor characteristics, particularly reliance on the androgen receptor pathway, will lead to personalized approaches to prostate cancer therapy.
PMID: 24775726 [PubMed - in process]
Source: Canadian Journal of Urology - December 1, 2014 Category: Urology & Nephrology Tags: Can J Urol Source Type: research
Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
CONCLUSIONS: The use of neoadjuvant docetaxel chemotherapy in patients with locally advanced PCa undergoing RP remains undefined. Results from this study are informative but only hypothesis generating given the study was not powered for survival. Mature data from the ongoing CALGB 90203 and GETUG-12 studies will shed light on this clinical question.
PMID: 25665510 [PubMed - as supplied by publisher]
Source: Urologic Oncology - February 6, 2015 Category: Urology & Nephrology Authors: Zhao B, Yerram NK, Gao T, Dreicer R, Klein EA Tags: Urol Oncol Source Type: research
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer
Our aim was to evaluate the clinical effectiveness of chemotherapy treatments currently licensed in Europe and recommended by the National Institute for Health and Care Excellence (NICE) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). A systematic search of MEDLINE, EMBASE and the Cochrane Library for randomised controlled trials (RCTs) published from 2001 to 2010 was carried out. Relative treatment effects for overall survival (OS) and progression-free survival (PFS) were estimated using standard meta-analysis and mixed treatment comparison methodology...
Source: Thorax - March 12, 2015 Category: Respiratory Medicine Authors: Pilkington, G., Boland, A., Brown, T., Oyee, J., Bagust, A., Dickson, R. Tags: Clinical trials (epidemiology), Lung cancer (oncology), Chemotherapy, Lung cancer (respiratory medicine), Internet Review Source Type: research
Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis.
Abstract
In this paper, we reviewed the long-term survival outcomes, safety, and quality-of-life of androgen-deprivation therapy (ADT) alone versus combined with radiation therapy (RT) or chemotherapy for locally advanced and metastatic prostate cancer (PCa). A literature search was performed using OvidSP. Randomized controlled trials (RCTs) that met the following criteria were included: including locally advanced or metastatic PCa, comparing ADT alone versus combined with any treatment method and reporting quantitative data of disease control or survival outcomes. Finally, eight RCTs met the inclusion criteria. A...
Source: Asian Journal of Andrology - April 7, 2015 Category: Urology & Nephrology Authors: Lei JH, Liu LR, Wei Q, Song TR, Yang L, Meng Y, Han P Tags: Asian J Androl Source Type: research
Taxane-containing regimens for metastatic breast cancer.
CONCLUSIONS: Taxane-containing regimens appear to improve overall survival, time to progression, and tumour response rate in women with metastatic breast cancer. Taxanes are also associated with an increased risk of neurotoxicity but less nausea and vomiting compared to non-taxane-containing regimens. The considerable heterogeneity encountered across studies probably reflects the varying efficacy of the comparator regimens used in these studies and indicates that taxane-containing regimens are more effective than some, but not all, non-taxane-containing regimens.
PMID: 26058962 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - June 9, 2015 Category: Journals (General) Authors: Ghersi D, Willson ML, Chan MM, Simes J, Donoghue E, Wilcken N Tags: Cochrane Database Syst Rev Source Type: research
Salvage Chemotherapy for Patients With Recurrent or Persistent Ovarian Clear Cell Carcinoma: A Retrospective Study of 164 Cases
Abstract: The purpose of this study was to evaluate the effects of salvage chemotherapy on recurrent or persistent ovarian clear cell carcinoma (CCC) with the goal of identifying a more rational treatment regimen for this lethal disease.
The medical records of patients with CCC were retrospectively reviewed to select patients that were subsequently treated for recurrent or persistent disease.
Of the 164 women with recurrent or persistent CCC, 485 chemotherapy courses with 1766 cycles were administered. Overall, the clinical benefit rate (CBR) was 39.4%, and the mean progression-free survival (PFS) was 4.5 months. Grade 3/4...
Source: Medicine - July 1, 2015 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
